Second-generation IL-2 receptor-targeted diphtheria fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma [Immunology and Inflammation]
Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-toxin–based fusion protein that depletes CD25-positive cells including regulatory T cells and has been approved for the treatment of persistent or recurrent cutaneous T cell lymphoma. However, the clinical use of denileukin diftitox was limited by vascular leak toxicity and production issues related to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Laurene S. Cheung, Juan Fu, Pankaj Kumar, Amit Kumar, Michael E. Urbanowski, Elizabeth A. Ihms, Sadiya Parveen, C. Korin Bullen, Garrett J. Patrick, Robert Harrison, John R. Murphy, Drew M. Pardoll, William R. Bishai Tags: Biological Sciences Source Type: research
More News: Academies | Allergy & Immunology | Cutaneous T cell lymphoma | Diphtheria | Lymphoma | Melanoma | Skin Cancer | T-cell Lymphoma | Toxicology